Soleno Therapeutics, Inc.

NasdaqCM:SLNO Stock Report

Market Cap: US$2.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Soleno Therapeutics Past Earnings Performance

Past criteria checks 3/6

Soleno Therapeutics's earnings have been declining at an average annual rate of -17.4%, while the Biotechs industry saw earnings growing at 31.9% annually. Revenues have been growing at an average rate of 100.3% per year. Soleno Therapeutics's return on equity is 19.4%, and it has net margins of 33.6%.

Key information

-17.40%

Earnings growth rate

26.68%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate100.33%
Return on equity19.37%
Net Margin33.55%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Mar 21

Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory

Summary Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic condition with no current FDA-approved treatments. Despite positive analyst ratings and a strong cash position, insider selling and competition from companies like Aardvark Therapeutics and Acadia Pharmaceuticals raise concerns. The PWS market is valued at $600 million, but Soleno's $2.2 billion market cap seems inflated given its limited pipeline and looming competition. An analysis around Soleno Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Feb 26

We're Hopeful That Soleno Therapeutics (NASDAQ:SLNO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 08

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 10

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Summary Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects. SLNO's robust cash position and recent equity raise ensure sufficient funding for DCCR's commercialization, reducing near-term dilution risks. Despite inherent biotech and market adoption risks, SLNO's favorable regulatory outlook and first-mover advantage in treating PWS hyperphagia justify a 'Strong Buy' rating. Read the full article on Seeking Alpha
Analysis Article • Mar 08

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, Soleno...

Revenue & Expenses Breakdown

How Soleno Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:SLNO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 262859615338
31 Dec 251902013241
30 Sep 2599-7812953
30 Jun 2533-18114474
31 Mar 250-19812777
31 Dec 240-17610679
30 Sep 240-1317366
30 Jun 240-652742
31 Mar 240-521934
31 Dec 230-391325
30 Sep 230-331220
30 Jun 230-281118
31 Mar 230-271017
31 Dec 220-241015
30 Sep 220-211015
30 Jun 220-231016
31 Mar 220-281018
31 Dec 210-311121
30 Sep 210-311023
30 Jun 210-311023
31 Mar 210-281024
31 Dec 200-25923
30 Sep 200-36823
30 Jun 200-27723
31 Mar 200-30720
31 Dec 190-31716
30 Sep 190-16713
30 Jun 190-19711
31 Mar 190-1679
31 Dec 180-1277
30 Sep 180-1676
30 Jun 180-1775
31 Mar 180-1374
31 Dec 170-1273
30 Sep 170-1362
30 Jun 170-1162
31 Mar 170-941
31 Dec 160-1062
30 Sep 160-873
30 Jun 160-1084
31 Mar 161-795
31 Dec 150-1060
30 Sep 150-2074
30 Jun 150-1954

Quality Earnings: SLNO has high quality earnings.

Growing Profit Margin: SLNO became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SLNO has become profitable over the past 5 years, growing earnings by -17.4% per year.

Accelerating Growth: SLNO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SLNO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (43%).

Return on Equity

High ROE: SLNO's Return on Equity (19.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 15:57
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soleno Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
François BriseboisCraig-Hallum Capital Group LLC